Slide 1: Second Quarter 2025 Earnings Presentation
Second Quarter 2025 Earnings Presentation August 1, 2025 1
Slide 2: Forward-Looking Statements; Non-GAAP Financial Information
Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements • factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill; This presentation contains “forward-looking statements” wi
Slide 3: A leading pharmacy and health care provider in the U.S.
A leading pharmacy and health care provider in the U.S., serving large and growing markets that have significant unmet needs, with high-quality and integrated services that improve outcomes and reduce cost 3
Slide 4: BrightSpring At A Glance
BrightSpring At A Glance Providing Needed Solutions ✓ Serving large and growing healthcare populations, characterized by high-cost, high-acuity, and significant complexity, with patient-centered and high-quality services delivered in preferred and lower-cost home and community settings Focus on Oper
Slide 5: BrightSpring Financial Highlights
BrightSpring Financial Highlights Second Quarter 2025 (for Continuing Operations) $3,148M 29.1% $143M 28.8% Revenue Revenue Growth Adj. EBITDA Adj. EBITDA Growth Second Quarter 2025 ($ in millions) Y/Y Growth Pharmacy Solutions Pharmacy Solutions Revenue $2,790 +32.0% acy Hom arm e an Infusion and S
Slide 6: Q2 2025 Revenue and Adjusted EBITDA Results (for Continuing Operations)
Q2 2025 Revenue and Adjusted EBITDA Results (for Continuing Operations) ($ in millions) Revenue Total Revenue +29.1% $3,148 $358 $2,438 Provider Services $324 +10.5% Pharmacy Solutions $2,790 $2,114 +32.0% Q2 2024 Q2 2025 ($ in millions) Adjusted EBITDA(1) Adj. EBITDA 4.5% 4.5% margin(1) Total Adjus
Slide 7: Q2 2025 Pharmacy Solutions Segment Performance (for Continuing Operations)
Q2 2025 Pharmacy Solutions Segment Performance (for Continuing Operations) ($ in millions) Q2 2025 Revenue Infusion and Specialty Pharmacy Home and Community Pharmacy Pharmacy Solutions $2,790 +32.0% $587 $2,114 Business Metrics +11.0% $528 $2,203 $1,586 +38.9% Prescriptions dispensed 10,852 (thousa
Slide 8: Q2 2025 Provider Services Segment Performance (for Continuing Operations)
Q2 2025 Provider Services Segment Performance (for Continuing Operations) ($ in millions) Q2 2025 Revenue Home Health Care Rehab Care Personal Care Provider Services +10.5% $358 $324 +3.8% $100 $96 Business Metrics $73 $70 +4.6% $158 +17.1% $185 Home Health Care average 30,085 daily census +6.4% y/y
Slide 9: Financial Performance: Three Months Ended June 30, 2025 (for Continuing Operations)
Financial Performance: Three Months Ended June 30, 2025 (for Continuing Operations) Three Months Ended June 30, 2024 vs. Three Months Ended June 30, 2025 Pharmacy Solutions Provider Services Three Months Three Months Three Months Three Months ($ in millions, Change ($ in millions, Change Ended June
Slide 10: 2025 Guidance, Excluding Community Living
2025 Guidance, Excluding Community Living 2025 Fiscal Year Guidance Prior Prior Prior Updated FY 2025 Guidance FY 2025 Guidance FY 2025 Guidance FY 2025 Guidance1 1 1 1 ($ in millions) Provided January 20, 2025 Provided March 6, 2025 Provided May 2, 2025 Provided August 1, 2025 $10,050 – $10,500 $10
Slide 11: De-leveraging Plan and Capital Allocation Priorities
De-leveraging Plan and Capital Allocation Priorities De-leveraging driven by operational performance and capital allocation Proforma • Capex investments: 1% of revenue Long-Term Pre IPO / Post-Equity and Debt Leverage Ratio Leverage Cash Flow • Sustainable net working capital position Transactions L
Slide 12: Appendix
Appendix 12
Slide 13: Historical Provider Services Financials, excluding Community Living
Historical Provider Services Financials, excluding Community Living FY23 and FY24 Provider Revenue and EBITDA Revenue Q1’23 Q2’23 Q3’23 Q4’23 FY23 Q1’24 Q2’24 Q3’24 Q4’24 FY24 Q1’25 Q2’25 ($ in millions) Home Health 134 135 141 147 557 148 158 168 182 655 178 185 Care Rehab Care 59 63 61 63 247 67 7
Slide 14: Continuing Operations Non-GAAP Reconciliations
Continuing Operations Non-GAAP Reconciliations For the Three Months Ended For the Six Months Ended ($ in thousands) June 30, 2024 June 30, 2025 June 30, 2024 June 30, 2025 Net income (loss) from Continuing Operations $ 8,486 $ 8,541 $ (47,541) $ 17,757 Income Tax (Benefit) Expense (13,115) 1,238 (39
Slide 15: Basic and Diluted Weighted-Average Shares Outstanding Calculation utilized in calculating Diluted EPS to Adjusted EPS
Basic and Diluted Weighted-Average Shares Outstanding Calculation utilized in calculating Diluted EPS to Adjusted EPS For the Three Months Ended (in thousands) Jun 30, 2024 Sept 30, 2024 Dec 31, 2024 Mar 31, 2025 Jun 30, 2025 Pre-IPO Shares (12/31/2023) 117,857 117,857 117,857 117,857 117,857 Initia